Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $202.00 Price Target at JPMorgan Chase & Co.

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price hoisted by JPMorgan Chase & Co. from $190.00 to $202.00 in a research note issued to investors on Monday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the specialty pharmaceutical company’s stock.

Several other equities research analysts have also recently issued reports on JAZZ. The Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 5th. They set a buy rating and a $169.00 price target on the stock. Morgan Stanley lowered their price target on Jazz Pharmaceuticals from $160.00 to $150.00 and set an equal weight rating for the company in a report on Friday, July 12th. Wells Fargo & Company cut their price objective on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an equal weight rating on the stock in a report on Thursday, August 1st. HC Wainwright reiterated a buy rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Finally, UBS Group reduced their price objective on Jazz Pharmaceuticals from $117.00 to $113.00 and set a neutral rating on the stock in a research note on Tuesday, July 2nd. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus target price of $173.07.

Jazz Pharmaceuticals Stock Up 3.0 %

Shares of NASDAQ JAZZ opened at $114.24 on Monday. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 1.90. The firm’s 50-day moving average is $108.89 and its two-hundred day moving average is $113.24. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $146.70. The company has a market capitalization of $7.20 billion, a PE ratio of 23.55, a price-to-earnings-growth ratio of 1.76 and a beta of 0.58.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in JAZZ. International Assets Investment Management LLC bought a new position in Jazz Pharmaceuticals in the 4th quarter worth approximately $7,201,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Jazz Pharmaceuticals by 29.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 39,113 shares of the specialty pharmaceutical company’s stock worth $4,811,000 after purchasing an additional 8,814 shares in the last quarter. Daiwa Securities Group Inc. raised its stake in shares of Jazz Pharmaceuticals by 15.5% during the fourth quarter. Daiwa Securities Group Inc. now owns 4,707 shares of the specialty pharmaceutical company’s stock valued at $579,000 after purchasing an additional 631 shares in the last quarter. abrdn plc grew its position in Jazz Pharmaceuticals by 442.2% in the 4th quarter. abrdn plc now owns 56,230 shares of the specialty pharmaceutical company’s stock valued at $6,916,000 after buying an additional 45,860 shares in the last quarter. Finally, Duality Advisers LP raised its position in shares of Jazz Pharmaceuticals by 35.8% during the 4th quarter. Duality Advisers LP now owns 25,641 shares of the specialty pharmaceutical company’s stock worth $3,154,000 after buying an additional 6,758 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.